Biotechnology specialist Applied Cells has launched its Mars Ingenuity Reagent kits for fast and easy cell isolation. This product line features both RUO and GMP-grade reagents, and has been specifically optimised for use on Applied Cells’ proprietary Mars Bar platform.

The platform provides in-flow Immunomagnetic cell isolation technology. The system offers positive and negative cell selection workflows, ensuring the separation of target cell subpopulations with purity, recovery, and viability.

  On April 29th, 2024, the FDA in the US granted full approval for  biotechnology company Seagen Inc.'s Tivdak (tisotumab vedotin) product, targeting tissue factor (TF) for the treatment of patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy.